Research into the androgen receptor as well as anabolic and androgenic hormones lead to the discovery of substances and chemicals called Selective Androgen Receptor Modulators (SARMs).

Early compounds were derived directly from testosterone molecules, but it didn’t take long for drug companies to find a way to develop nonsteroidal compounds. Over the past almost 80 years, researchers and drug companies have been looking at ways to improve the overall bioavailability of these chemical compounds while at the same time reducing their hepatic toxicity.

Ligand Pharmaceuticals was the very first drug company on the planet to produce a nonsteroidal SARM, and they are the same company responsible for producing LGD4033.

Just what is LGD4033, anyway?

Classified as an “orally active, nonsteroidal Selective Androgen Receptor Modulator”, LGD4033 was initially designed to help fight back against muscle wasting diseases and conditions while at the same time decreasing the amount of bone turnover (caused by diseases like osteoporosis).

Currently in Phase 1 of clinical trials, this chemical compound shows no sign of decreasing LH figures or FSH figures and also has shown zero evidence of increasing PSA or estradiol counts, either. At the same time, it has shown some evidence of negatively impacting overall testosterone levels as well as free testosterone levels. SHBG levels have also been found to decrease with long-term exposure to the compounds in LGD4033.

Because of those factors, LGD4033 is often combined with a Post Cycle Therapy (PCT) compound used to reboot traditional testosterone production.

LGD4033 also has a unique chemical composition in that it can be combined with a host of other SARMs without any negative or ill effects. In fact, early research shows that the impact of LGD4033

Researchers are trying to determine whether or not LGD4033 is available to activate AMPK, the specific mechanism that dictates fat oxidation and Lipolysis. As of right now, researchers also aren’t aware of whether or not LGD4033 has the ability to impact trabecular bone turnover though there have been early signs of improvement in and of cortical bone turnover when these chemical compounds are introduced.

Like most of the other SARMs that have been produced in the past 80 years, LGD4033 has in antagonistic activity in the androgenic organs. This dramatically reduces the impact on the prostate, something that traditional anabolic steroids and other chemical substances cannot claim.

LGD4033 is one of the few chemical compounds that can activate androgen receptors across the board, rather than selectively targeting only a handful of androgen receptors while leaving most others dormant. This allows for improvements in protein synthesis and nitrogen retention, two big pieces of the puzzle that pharmaceutical operations are looking to optimize these kinds of drugs.

Bioavailability of LGD4033 is high, particularly since it is an orally available solution. This means that far more of the chemical compounds contained within LGD4033 reach the bloodstream, and a higher level of these chemical compounds are then shuttled off to androgen receptors rather than being quickly and efficiently passed out of the body with the normal waste removing functions.

More long-term research is necessary to fully understand the potential positive and negative impacts of LGD4033 and its fellow SARMs, but as of right now it is one of the most popular and reliable options on the market today.